ROCK, GSK3 and MEK pathway inhibitors (Fate Therapeutics)

N/A

Report date: 2025/01/26 16:30:32

Base Information

Drug NameROCK, GSK3 and MEK pathway inhibitors (Fate Therapeutics)

Drug Alias Namepharmacologically modified hematopoietic stem cell therapy (Fate Therapeutics)

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase inhibitorsRho-associated protein kinase 1 inhibitorsGlycogen synthase kinase-3 alpha inhibitors

TargetsGlycogen synthase kinase-3 alphaDual specificity mitogen-activated protein kinase kinaseRho-associated protein kinase 1

Therapy Area/IndicationsGenetic Diseases, Inborn

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFate Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsGenetic Diseases, Inborn

Inactive IndicationsN/A

Other Information

ATC CodeN/A